Ra Pharmaceuticals (NASDAQ:RARX)‘s stock had its “buy” rating reiterated by analysts at Royal Bank Of Canada in a report released on Tuesday. They currently have a $18.00 price objective on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 125.85% from the company’s current price.

RARX has been the topic of several other reports. Zacks Investment Research raised Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 target price (up from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday. Jefferies Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Ra Pharmaceuticals in a research report on Thursday, September 28th. Finally, Credit Suisse Group increased their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.20.

Shares of Ra Pharmaceuticals (NASDAQ RARX) traded down $0.95 during trading on Tuesday, hitting $7.97. The company’s stock had a trading volume of 1,110,821 shares, compared to its average volume of 131,546. Ra Pharmaceuticals has a one year low of $7.86 and a one year high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.06). sell-side analysts expect that Ra Pharmaceuticals will post -2.46 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Tekla Capital Management LLC acquired a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $7,418,000. Citadel Advisors LLC acquired a new stake in Ra Pharmaceuticals in the 3rd quarter valued at $4,664,000. Numeric Investors LLC acquired a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $2,484,000. Nexthera Capital LP acquired a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $1,912,000. Finally, Sectoral Asset Management Inc increased its holdings in Ra Pharmaceuticals by 55.6% in the 3rd quarter. Sectoral Asset Management Inc now owns 278,082 shares of the company’s stock valued at $4,060,000 after purchasing an additional 99,332 shares in the last quarter. 69.64% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Ra Pharmaceuticals (RARX) Given “Buy” Rating at Royal Bank Of Canada” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/05/ra-pharmaceuticals-rarx-given-buy-rating-at-royal-bank-of-canada.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.